Aptose Biosciences Completes $8 Million Public OfferingSAN DIEGO and TORONTO – Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) announced the successful closure of its public offering on November 25, 2024. The Canadian corporation completed the offer

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Aptose Biosciences’s 8K filing here.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.